TY - JOUR
AR - JICOA-2021-4-104
TI - Empiric Treatment of Foot Infection in Patients with Severe Diabetes
AU - Alexandre Sacchetti, Bezerra
AU - Flavia Altheman, Loureiro
AU - Carla Maria, Pasquareli Vazquez
AU - Afonso Cesar, Polimanti
AU - Rafi Felicio, Bauab Dauar
JO - Journal of Integrative Cardiology Open Access
PY - 2021
DA - Wed 08, Dec 2021
SN - 2674-2489
DO - http://dx.doi.org/10.31487/j.JICOA.2021.04.04
UR - https://www.sciencerepository.org/empiric-treatment-of-foot_JICOA-2021-4-104 
KW - Foot infection, diabetes, diabetic patients, cultures, antibiotics
AB - Background: Despite being treated with antibiotics of broad spectrum recommended by International Consensus, severe diabetic patients with lower limb infection do not present a positive clinical evolution during empirical treatment. This study’s bacterial profile was analysed and compared with other worldwide hospital centers. 
Objective: To confirm the need of an individualized empirical treatment for severe diabetic patients with foot infection. 
Methods: Retrospective analysis of cultures and antibiograms of severe diabetic patients admitted by foot infection. 
Results: The results were consistent with the socioeconomic realities of developing countries. Gram-negative bacteria (52,11%) were present in most bone cultures. Results presented a high incidence of Enterococcus faecalis in both gram-positive (21,2%) and polymicrobial (34,7%) samples. Bacterial resistance with the use of ordinary antibiotics in the statistical analysis was high. 
Conclusion: The community infections should undergo broad spectrum empirical therapy combining amikacin (80,43%) or meropenem (72,00%) with gram-negative and vancomycin (100%) or teicoplanin (90,00%) or linezolid (74,19%) with gram-positive.